Please ensure Javascript is enabled for purposes of website accessibility

What You'll Want to Know About Geron's Q2 Results

By Keith Speights - Aug 2, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There wasn't much good news for the small biotech in Q2. But Geron continues to plug away with its imetelstat program.

Investors weren't too happy the last time Geron (GERN 8.53%) announced quarterly results in May. Revenue dropped 82%, and the small biotech's net loss widened. Later in the month, Geron disappointed investors even more with its announcement of a delay in the decision regarding imetelstat's potential development as a treatment for patients with myelofibrosis who are at "intermediate-2" or high risk.

Anyone hoping for great news from Geron when the company reported its Q2 earnings release on Thursday after the market closed were let down yet again. Here's what you need to know from the biotech's Q2 update. 

Scientist in lab holding up a test tube

Image source: Getty Images.

By the numbers

Geron announced Q2 revenue of $101,000. This marked a steep decline from the $208,000 reported in the same quarter of 2018. The total, however, was slightly above the average analysts' revenue estimate of $100,000.

The company reported a net loss on a generally accepted accounting principles (GAAP) basis of $14.2 million, or $0.08 per share. In the prior-year period, Geron posted a net loss of $6.9 million, or $0.04 per share. The consensus analysts' estimate called for a Q2 net loss of $0.09 per share.

Geron ended the second quarter with cash and marketable securities totaling $162.3 million. The company has raised net cash of around $2.6 million since May through issuing nearly 1.9 million shares of common stock. 

Behind the numbers

Geron's revenue plunged because of a reduction in the number of active research license agreements in place. Patent expiration on the underlying technology of the company's human telomerase reverse transcriptase (hTERT) technology is the main culprit behind the drop in research license agreements.

The biotech's net loss worsened in the second quarter, in part because of the decline in revenue. Geron's operating expenses also more than doubled from the prior-year period to $15.3 million. This increase stemmed from higher research and development costs from resuming sponsorship of the ongoing imetelstat clinical trials and higher general and administrative spending primarily related to increased corporate, legal, and staffing costs.

Did anything move in the right direction for Geron in Q2 from a financial perspective? Yes, but it wasn't a big item. The company announced that its interest and other income rose from $717,000 in the prior-year period to $1.1 million in the second quarter of 2019. Higher yields on its marketable securities fueled this increase.

Looking ahead

Geron anticipates total operating expenses for the full-year will be between $80 million and $85 million. This includes a $20 million to $25 million one-time cost with imetelstat program transition activities from Johnson & Johnson's Janssen subsidiary. Geron expects the transition of the imetelstat program from Janssen will wrap up in the third quarter of 2019.

The company also has a lot going on related to advancing its imetelstat program. The two-part IMerge clinical study is getting cranked up to evaluate the drug in treating transfusion-dependent patients with lower-risk myelodysplastic syndromes (MDS).

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
GERN
$1.40 (8.53%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.